TARGETED DIAGNOSIS OF BLADDER AND URETERAL CARCINOMA USING RADIOLABELED BDI-1

The aim of this study is to investigate the possibility of radioimmuno imaging (RII) by radiolabelled anti-bladder carcinoma monoclonal antib ody BDI-1 applied to diagnosis of bladder cancer and ureteral cancer. BDI-1 was labelled with I-131 and Tc-99m. The immunoreactivity, pharma cokinetics and biodistribution in mice were studied. RII was performed in 46 patients. The results showed that I-131, Tc-99m-BDI-1 have sati sfactory immunoreactivity and excellent tumor-locating properties. The blood clearance half-life T(1/2)alpha and T(1/2)beta were 35 h in the first phase and 151 h in the second phase, respectively. Thirty-nine patients were studied by an intravesical administration method; the se nsitivity was 90.5%. Seven patients were studied by an intravenous adm inistration method. The RII results of three cases with primary or rec urrent bladder cancer and three cases with ureteral cancer were confir med histologically. RII was negative in one patient with suspected lun g metastasis that was shown on radiography. The investigation revealed that RII can be used as an auxiliary method for the detection of blad der cancer and may be valuable for the diagnosis of ureteral cancer.